IMP321 Phase 1 Study in Advanced or Metastatic Renal Cell Carcinoma Patients (P003)
Phase of Trial: Phase I
Latest Information Update: 24 Nov 2015
At a glance
- Drugs Eftilagimod alpha (Primary)
- Indications Renal cancer; Renal cell carcinoma
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Immutep
- 12 Jan 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 12 Jan 2010 Actual patient number (24) added as reported by ClinicalTrials.gov.
- 26 Apr 2008 The expected completion date for this trial has been extended from 1 Apr 2008 to 1 Nov 2008.